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Structural variations of the human brain are heritable and highly polygenic traits, with hun-
dreds of associated genes identified in recent genome-wide association studies (GWAS).
Transcriptome-wide association studies (TWAS) can both prioritize these GWAS findings
and also identify additional gene-trait associations. Here we perform cross-tissue TWAS
analysis of 211 structural neuroimaging and discover 278 associated genes exceeding Bon-
ferroni significance threshold of 1.04 × 10−8. The TWAS-significant genes for brain structures
have been linked to a wide range of complex traits in different domains. Through TWAS
gene-based polygenic risk scores (PRS) prediction, we find that TWAS PRS gains substantial
power in association analysis compared to conventional variant-based GWAS PRS, and up to
6.97% of phenotypic variance (p-value= 7.56 × 10−31) can be explained in independent
testing data sets. In conclusion, our study illustrates that TWAS can be a powerful supple-
ment to traditional GWAS in imaging genetics studies for gene discovery-validation, genetic
co-architecture analysis, and polygenic risk prediction.
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Variations in brain structure and microstructure acrossindividuals are associated with many neurological andpsychiatric (referred to as neuropsychiatric hereafter)
traits including cognitive functions1–5, neurodegenerative, neu-
rodevelopmental, and psychiatric disorders6–9, as well as alcohol
and tobacco consumption10, and physical bone density11. Struc-
tural variations of human brain can be quantified by multimodal
magnetic resonance imaging (MRI). Specifically, the T1-weighted
MRI (T1-MRI) can provide basic morphometric information of
brain tissues, such as volume, surface area, sulcal depth, and
cortical thickness. In region of interest (ROI)-based T1-MRI
analysis, images are annotated onto ROIs of pre-defined brain
atlas, and then both global (e.g., whole brain, gray matter, white
matter) and local (e.g., basal ganglia structures, limbic, and
diencephalic regions) markers can be generated to measure the
brain anatomy. On the other hand, diffusion MRI (dMRI) can
capture local tissue microstructure through the random move-
ment of water. Using diffusion tensor imaging (DTI) models,
brain structural connectivity can be quantified by using white
matter tracts extracted from dMRI, which build psychical con-
nections among brain ROIs and are involved in connected net-
works for various brain functions12,13. See Miller et al.11 and
Elliott et al.14 for a global overview and more information about
neuroimaging modalities used in the present study.
Structural neuroimaging traits have shown moderate-to-high
degree of heritability in both twin and population-based
studies14–24. In the past decade, genome-wide association stu-
dies (GWAS)14,24–34 have been conducted to identify the
associated genetic variants (typically single-nucleotide poly-
morphisms [SNPs]) for brain structures. A highly polygenic35,36
genetic architecture has been observed, indicating that a large
number of genetic variants contribute to variations in brain
structure measured by neuroimaging biomarkers21,37. Particu-
larly, using data from the UK Biobank (UKB38) cohort, two
recent large-scale GWAS have identified 578 associated genes for
101 regional brain volumes derived from T1-MRI39 (referred to
as ROI volumes, n= 19,629) and 110 DTI parameters of dMRI40
(referred as DTI parameters, n= 17,706). Some of these dis-
covered genes had been implicated for neuropsychiatric diseases
or traits by previous GWAS. However, most of them have not
been verified and need further investigations. Complementary to
traditional GWAS, transcriptome-wide association studies
(TWAS) have become increasingly adopted in gene-trait asso-
ciation analysis thanks to recent advances in gene expression
imputation methods41–47 and burgeoning generation of such
expression imputation reference data sets (e.g., the Genotype-
Tissue Expression (GTEx) project48). Despite some challenges49
such as interpreting causality, TWAS has successfully discovered
additional gene-trait associations and provided insights into
biological mechanisms for many complex traits50. Through
imputed transcriptomes, TWAS can reduce the multiple testing
burden and leverage gene expression data to increase testing
power for gene-trait association detection. This is a particularly
desirable feature for imaging genetics studies, for which most
neuroimaging GWAS data sets continue to have small sample
sizes and heavy multiple testing burden51.
In this work, we performed TWAS analysis for 211 structural
neuroimaging traits including 101 ROI volumes and 110 DTI
parameters. As these brain-related traits tend to be highly
polygenic21,37 and are related to many traits across a range of
categories11, we used a cross-tissue (panel) TWAS approach
(UTMOST43) in our main analysis. UTMOST first performs
single-tissue gene-trait association analysis in each reference
panel with both within-tissue and cross-tissue statistical penalties,
and then combines these single-tissue results using the General-
ized Berk-Jones (GBJ) test52, which accommodates tissue
dependence and can account for the potential sharing of local
expression regulation across tissues. The UKB data set was used
in the discovery phase (n= 19,629 for ROI volumes and 17,706
for DTI parameters, respectively). For the discovery UKB cohort,
we compared TWAS-significant genes with previous GWAS
findings in gene-based association analysis via MAGMA53 and
gene-level functional mapping and annotation results by
FUMA54. The UKB TWAS results were validated in five inde-
pendent data sources, including Philadelphia Neurodevelop-
mental Cohort (PNC55, n= 537), Alzheimer’s Disease
Neuroimaging Initiative (ADNI56, n= 860), Pediatric Imaging,
Neurocognition, and Genetics (PING57, n= 461), the Human
Connectome Project (HCP58, n= 334), and the ENIGMA224 and
ENIGMA-CHARGE collaboration34 (n= 13,193, for eight ROI
volume traits, referred as ENIGMA in this paper). Chromatin
interaction enrichment analysis was conducted for TWAS-
significant genes. Finally, we developed TWAS gene-based poly-
genic risk scores59 (PRS) using FUSION41 to fully assess poly-
genic architecture and examine the predictive capability of the
UKB TWAS results.
Results
Overview of TWAS discovery-validation in the six data sets.
We conducted a two-phase discovery-validation TWAS analysis
for 211 neuroimaging traits by using the UKB cohort for dis-
covery and the other data sets (ADNI, HCP, PING, PNC, and
ENIGMA) for validation. We applied the UTMOST gene
expression imputation models trained on GTEx tissues, and used
GWAS summary statistics generated from previous GWAS as
inputs. We refer to 1.04 × 10−8 (that is, 5 × 10−2/22,694/211,
adjusted for all candidate genes and traits performed) as the
significance threshold for gene-trait associations unless otherwise
stated. The original version of UTMOST models was trained
using GTEx v6 as the reference. In this study, we retrained the
UTMOST models using the recently released GTEx v8 data and
performed our analysis using both versions. As the GTEx v6 and
v8 databases share individual-level samples, we are particularly
interested in the associations that can be consistently detected in
the two versions. Therefore, in the rest of this paper we reported
genes that were either (1) significant in both versions; or (2)
significant in one version and were within ±1MB window with at
least one significant gene in the other version (Methods).
The UKB discovery phase identified 918 significant gene-trait
associations (Supplementary Data 1) between 278 genes and 152
neuroimaging traits (57 ROI volumes, 95 DTI parameters). Of the
278 TWAS-significant genes, 90 (32.4%) had significant associa-
tions with more than two neuroimaging traits, 16 (10.4%) had
more than five significant associations, and 16 (5.8%) had at least
ten, including POLR2F, TREH OR1F12, FOXF1, LRRC37A,
AC008105.1, MAPT, ARHGAP27, EIF4EBP3, PLEKHM1,
ZKSCAN4, CCDC157, XRCC4, AC005670.1, CRHR1, and
RECQL4. These 16 genes together contributed 344 (37.5%) of
the 918 gene-trait associations, indicating their widespread
influences on brain structures. Specifically, we identified 173
genes whose imputed gene expression levels were significantly
associated with one or more of the 57 ROI volumes (328
associations in total, 186 additional, Supplementary Fig. 1), and
140 significantly associated genes (35 overlappings) for one or
more of the 95 DTI parameters (590 associations in total, 277
additional, Supplementary Fig. 2).
Figure 1 illustrates that TWAS prioritized previous GWAS
findings of MAGMA and FUMA and also discovered many
additional associations and genes. Moreover, some genes were
associated with both ROI volumes and DTI parameters, while
others were more specifically related to certain structures
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(Supplementary Fig. 3). For example, XRCC4, ZKSCAN4,
EIF4EBP3, and CD14 were associated with DTI parameters but
not ROI volumes, DEFB124, COX4I2, HCK, HM13, and REM1
showed associations with putamen and pallidum volumes, and
the associations of PLEKHM1, LRRC37A, MAPT, AC005670.1,
RECQL4, ARHGAP27, and CRHR1 were spread widely across
DTI parameters and total brain volume.
We validated the UKB results in the other five independent
cohorts. For each data set, we applied the Bonferroni-corrected
significance threshold accounting for all candidate genes and
traits analyzed (that is, 5 × 10−2/22,694/number of traits,
Supplementary Data 2–6). We found that 19 additional UKB
TWAS-significant genes (NPSR1, TREH, CRYBA1, MFRP,
SLX1B, RPL13AP3, GALP, KCNH7, DCTPP1, LINC02454,
JPH3, IL4, HCK, TIMM8AP1, LGALS3, LINC02057, RECQL4,
DLGAP5, and AC090666.1) can be validated in one or more of the
five data sets. These data sets also replicated six previous UKB
GWAS-significant genes (NUP210L, MIR1-1HG, DOK5,
KRTAP5-1, AC008393.1, and DPP4), and four genes that were
significant in both UKB TWAS and GWAS (DCC, LRRC37A,
ANKRD42, and DLG2) (Supplementary Fig. 4). The TWAS
additional findings and validated genes were discussed further in
detail below.
Additional TWAS discoveries and validated genes. Of the 278
UKB TWAS-significant genes, 159 were not discovered in pre-
vious GWAS of the same UKB data set (Supplementary Data 7).
TWAS resulted in 102 additional associated genes for 54 ROI
volumes (186 associations, Supplementary Fig. 5), and 75 addi-
tional genes for 90 DTI parameters (277 associations, Supple-
mentary Fig. 6). According to NHGRI-EBI GWAS catalog60, the
159 TWAS-significant genes replicated 21 previous findings on
brain structures, including JPH361 for hippocampal volume in
mild cognitive impairment, CRYBA133 for brain stem volume
measurement, AC145285.233 for caudate nucleus volume, and










































































































































































































































































































































































































































































Fig. 1 Selected significant gene-trait associations discovered in UKB (UK Biobank) cross-tissue TWAS analysis of 211 neuroimaging traits (n=
19,629 subjects for ROI volumes and 17,706 for DTI parameters). The gene-level associations were estimated and tested by the cross-tissue UTMOST
approach (https://github.com/Joker-Jerome/UTMOST). We used the p value threshold of 1.04 × 10−8, corresponding to adjusting for testing 211 imaging
phenotypes with the Bonferroni correction. The x axis provides the IDs of the neuroimaging traits, and the y axis lists the detected genes in TWAS. The
additional (UTMOST new) and previously reported GWAS-significant associations (MAGMA, FUMA, and FUMA&MAGMA) were labeled with different
colors (orange, purple, green, and red, respectively).
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genes had not been linked to brain structure previously and thus
can be regarded as additional genes for these 211 neuroimaging
traits. To explore the genetic overlaps with other traits in different
domains, we performed association lookups for the 159 TWAS
genes on the NHGRI-EBI GWAS catalog. Figure 2 shows that
these genes were widely associated with anthropometric measures
(e.g., height, waist-to-hip ratio, heel bone mineral density, body
mass index), neuropsychiatric traits (e.g., cognitive function,
intelligence, math ability, schizophrenia, bipolar disorder, Alz-
heimer’s disease), coronary artery disease, mean corpuscular
hemoglobin, neuroticism, education, reaction time, chronotype,
smoking behavior, and alcohol use, such as ELL63–65, SH2B166–69,
IL2768,70, KCNH771,72, HYI73,74, and GNAT175,76.
For the 29 TWAS-validated genes shown in Supplementary
Fig. 4, ten (ANKRD42, DCC, LRRC37A, NUP210L, DOK5,
KRTAP5-1, MIR1-1HG, AC008393.1, DLG2, and DPP4) of them
had been discovered in the previous UKB GWAS and were
implicated in brain-related complex traits, such as neuroticism77,
major depression78, schizophrenia75,79,80, Intelligence70, math
ability72, reaction time68, and insomnia81. The remaining 19
genes, which are additional findings from our TWAS analysis,
also had known associations with various neuropsychiatric traits.
For example, previous GWAS reported that HCK was associated
with chronotype81, LGALS3 with schizophrenia82, AC090666.1
with neuroticism71, CRYBA1 with depression78, RECQL4 with
cognitive ability68, KCNH7 with cognitive performance72 and
reaction time68, and JPH3 with bipolar disorder83 and cognitive
impairment61. Moreover, we found that DCC, MIR1-1HG, DPP4,
and RECQL4 were specifically associated with brain-related traits
and disorders, while other genes (such as NUP210L, DLG2,
AC090666.1, KCNH7, and JPH3) were also widely associated with
non-brain traits, including triglycerides84, mean platelet
volume64, and coronary artery disease85. In summary, TWAS
additional and validated genes expand the overview of gene-level
pleiotropy across these traits, suggesting that neuroimaging-
derived biomarkers could be useful in studying a wide range of
complex traits.
Comparing power to detect the association between brain tis-
sues and all tissues. As a comparison, we performed a brain
tissue-specific version of UTMOST TWAS that only combined
brain tissues (10 brain tissues in GTEx v6 or 13 brain tissues in
GTEx v8, Method). This brain tissue-specific TWAS detected
396 significant gene-trait associations (Supplementary Data 8)
between 134 unique genes and 81 neuroimaging traits, including
84 associated genes for one or more of 29 ROI volumes (136
associations, Supplementary Fig. 7), and 68 genes (18 over-
lapping) for one or more of 52 DTI parameters (260 associations,
Supplementary Fig. 8).
Most (119/134) of the brain tissue-specific genes have been
identified by either the cross-tissue TWAS (117/134) or previous
GWAS (65/134). The 15 genes that were uniquely identified by
brain tissue-specific analysis included DNAJC2, LHFPL3, NUPR1,
UQCRQ, BCL2L1, MBD2, KNCN, NUFIP2, MIB2, C3orf62,
CDHR4, FXYD1, TMEM173, ZSCAN31, and PI4KAP2. Among
them, LHFPL3 showed associations with education86, social
behavior87,88, cognitive ability68, schizophrenia89, and bipolar
disorder90. MBD2 was associated with reaction time68, ZSCAN31
with schizophrenia89 and cross disorders91, and NUPR1, CDHR4,
and C3orf62 with intelligence81,92.
Compared with brain tissue-specific TWAS, the cross-tissue
analysis clearly identified more signals. For example, of the 328
gene-trait associations identified by cross-tissue analysis of ROI
volumes, 142 had been identified in GWAS, 50 can be
additionally identified by brain tissue-specific TWAS, and 136
can only be detected by cross-tissue analysis (Supplementary
Fig. 9). Similarly, 313 of the 590 cross-tissue TWAS associations
for DTI can be identified in GWAS, 90 can be additionally
identified by brain tissue-specific TWAS, and 187 were cross-
tissue TWAS only (Supplementary Fig. 10). These results
illustrate the advantage of cross-tissue analysis over brain
tissue-specific TWAS for discovering association signals that are
difficult to be identified in traditional GWAS. We further
compared their results in a few follow-up analyses below.
Comparison with GWAS variant-level signals and conditional
analysis. For each of the 918 gene-trait associations detected in
cross-tissue TWAS, we used previous GWAS summary statistics
to check the most significant variant within the gene region (with
a 1MB window on each side) that was pinpointed in the same
UKB data set (Method). The GWAS p value of the most sig-











































































































































































































































































































































































Fig. 2 Cross-tissue TWAS-significant genes of neuroimaging traits (n= 19,629 subjects for ROI volumes and 17,706 for DTI parameters) that have
been linked to other complex traits in previous GWAS. For each of the cross-tissue TWAS-significant genes listed in the x axis, we manually checked the
previously reported associations on the NHGRI-EBI GWAS catalog (https://www.ebi.ac.uk/gwas/). The genes associated with DTI parameters (DTI), ROI
volumes (volume), and both of them (Both) were labeled with three different colors (blue, orange, and green, respectively).
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>1 × 10−6 for associations of 19 genes (Supplementary Data 9).
None of them had been identified by MAGMA or FUMA, indi-
cating that it can be difficult to detect these genes by GWAS or
post-GWAS screening for any of these neuroimaging traits. Of
the 19 genes, seven (GALP, LINC02057, CRYBA1 TREH, IL4,
DCTPP1, RECQL4) were validated in one or more of the five
validation data sets and were discussed in the previous section.
For the other 12 genes (LGALS16, MYO9A, FAM83C, CEA-
CAMP3, H4C11, AC005670.1, OR10V3P, TMEM136, CELSR3,
TMEM101, CCDC157, and GDF5) genes, MYO9A was reported
for defects in the structure and function of the neuromuscular
junction93, FAM83 family was linked to certain brain tumors94,
CELSR3 was associated with education71 and cognitive
ability70,77, and CCDC157 was found to be associated with white
matter microstructure in other data sets95. The same checking
was then performed for the 396 significant gene-trait associations
of brain tissue-specific TWAS. We found that only DCTPP1 and
CCDC157 had minimum GWAS p value <1 × 10−6 (Supple-
mentary Data 10).
We next performed a conditional analysis to see whether the
TWAS signals remained significant after adjustment for the most
significant genetic variant used in UTMOST gene expression
imputation models (Method). Although our cross-tissue analysis
combined information from many genetic variants across various
human tissues, we found that 472 associations may indeed be
dominated by the strongest GWAS signal of the imputation model,
as their conditional p-values were larger than 0.05 (Supplementary
Data 11). However, the conditional p values of eight genes (WIF1,
XRCC4, C15orf56, CCDC53, RPSAP52, CCDC157, AMZ1, NMT1)
were smaller than 1 × 10−6 for 23 gene-trait associations,
suggesting that these associations were unlikely to be driven by a
signal genetic variant. When the p value threshold was relaxed to
1 × 10−3, 118 associations of 42 genes persisted after conditional
analysis. Similar conditional analysis was also performed on
significant associations of brain tissue-specific TWAS. The
conditional p values were smaller than 1 × 10−6 for five genes
(XRCC4, C15orf56, NMT1, CCDC157, AMZ1) with 20 associations,
and were smaller than 1 × 10−3 for 25 genes with 84 associations
(Supplementary Data 12).
Chromatin interaction enrichment and genetic overlaps. To
explore the biological interpretations of TWAS and GWAS-
significant genes, we performed enrichment analysis in promoter-
related chromatin interactions of four types of brain cells96
(induced pluripotent stem cells (iPSC)-induced excitatory neu-
rons, iPSC-derived hippocampal DG-like neurons, iPSC-induced
lower motor neurons, and primary astrocytes) (Method). Both
GWAS and cross-tissue TWAS-significant genes were sig-
nificantly enriched in chromatin interactions of astrocytic glial
cells (Supplementary Data 13, Wilcoxon rank test, p value < 2.8 ×
10−2), and combining GWAS and cross-tissue TWAS-significant
genes resulted in a smaller p value (1.04 × 10−3). Cross-tissue
TWAS-significant genes were also significantly enriched in
chromatin interactions from two neuron types (excitatory and
lower motor neurons). For all of the three neuron types, cross-
tissue TWAS-significant genes had smaller enrichment p values
(p value range= [2.3 × 10−2, 6.18 × 10−2]) than those of GWAS-
significant genes (p value range= [0.11, 0.57]). Overall, these
results suggest that cross-tissue TWAS-significant genes were
more actively interacted with other chromatin regions and may
play a more important role in regulating gene expressions as
compared with other genes. In contrast, brain tissue-specific
TWAS-significant genes did not show any significant enrichment
(p value range= [0.14, 0.68]), indicating the value of cross-tissue
TWAS over brain tissue-specific TWAS.
Next, we applied fastENLOC97 to perform colocalization
analysis for the 278 cross-tissue TWAS-significant genes
(Methods). We found that 96 of the 278 (34.5%) genes (involving
233 of 918 gene-trait associations) had regional colocalization
probability (RCP) > 0.1 in at least one tissue type and seven genes
(involving 17 gene-trait associations) had RCP > 0.9 (Supplemen-
tary Data 14). Among them, there are known risk genes. For
example, SLC16A8 is a known risk gene of glioma/
glioblastomas98. In our cross-tissue TWAS analysis, SLC16A8
was significantly associated with multiple white matter micro-
structure traits, and fastENLOC colocalization analysis also found
that SLC16A8 had a high colocalization probability (0.919) with
expression quantitative trait loci (eQTL) signals in GTEx v8 nerve
tibial tissue type.
To further explore the gene-level genetic overlaps among brain
structure and other complex traits and clinical outcomes, we
performed cross-tissue TWAS analysis for 16 other brain-related
complex traits with a large GWAS sample size, including
neuropsychiatric traits, cognition, and cardiovascular risk factors
(Supplementary Data 15). We found that 112 of the 278 cross-
tissue TWAS-significant genes of neuroimaging traits were also
significantly associated with one or more of 14 traits (that is, 5 ×
10−2/22,694/16, Supplementary Data 16, Fig. 3). These results
suggest the genes involved in brain structure changes are often
related to vascular risk factors and are also active in brain
functions and neuropsychiatric disorder/diseases. For example, we
found 65 overlapping genes with cognitive function, 54 with
education, 53 with numerical reasoning, 50 with intelligence, 39
with neuroticism, 37 with drinking behavior, and 22 with
schizophrenia. A large proportion (83/112) of these genes were
associated with more than one neuropsychiatric traits, and 13
genes were linked to more than five traits, including NSF, LRP4,
ZSCAN9, CRHR1, ARHGAP27, RECQL4, C1QTNF4, KCNH7,
MAPT, FAM180B, AC005829.1, AC005670.1, and AC090666.1,
indicating the high degree of statistical pleiotropy99 of these genes.
We next performed some additional analysis for the 19 validated
UKB TWAS additional genes. First, we found that JPH3 has a high
probability of being loss-of-function (LoF) intolerant100 (pLI=
0.986), indicating its intolerant of LoF variation. JPH3 has also been
reported for brain disorders, including Huntington disease101,102,
Huntington Disease-Like 2101,103, spinocerebellar ataxia101, and
Dentatorubral-pallidoluysian atrophy104. Second, DCTPP1 and
DLGAP5 were also identified by a recent eQTL study of developing
human brain105. Moreover, LGALS3 and DLGAP5 were within the
mitotic progenitors and cell division function module in the
constructed transcriptional networks106, and JPH3 was within the
adult neurons, synaptic transmission, and neuron projection
development function module, indicating their potential functions
in biological processes of brain development. In addition, NPSR1,
GALP, KCNH7, JPH3, IL4, and LGALS3 mutations have been
reported to be related with behavior/neurological phenotypes in
mice (Mouse Genome Informatics, http://www.informatics.jax.org/).
TWAS gene-based polygenic risk scores analysis. To fully assess
the polygenic genetic architecture of neuroimaging traits and
examine the predictive ability of UKB TWAS results, we con-
structed TWAS gene-based PRS on subjects in PNC, HCP, PING,
and ADNI cohorts for all of the 211 neuroimaging traits
(Method). The prediction analysis was conducted separately on
52 reference panels (13 GETx v7 brain tissues, 35 GTEx v7 other
tissues, 1 non-GETx brain tissue, and 3 non-GETx other tissues)
using the FUSION41 software and database. We found that
genetically predicted profiles for 28 ROI volumes (Fig. 4) and 23
DTI parameters (Supplementary Fig. 11) were significantly
associated with the corresponding observed traits in all testing
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data sets after Bonferroni correction (that is, 101 × 4+ 3 × 110=
734 tests). Compared with previous SNP-based PRS analysis that
yielded significant PRS profiles for 11 ROI volumes39, gene-based
PRS profiles were significant for more ROI volumes, such as left/
right insula, left/right pallidum, left/right ventral DC, left/right
fusiform, and left/right transverse temporal, suggesting the sub-
stantial power gain in association analysis of PRS. The significant
TWAS PRS can account for 0.97–6.97% phenotypic variance (p
value range= [8.0 × 10−29, 6.81 × 10−5]) (Supplementary
Data 17–18), which was within a similar range to SNP-based PRS
analysis (1.17–6.38%)39. For example, the (incremental) R2 of
TWAS PRS of cerebellar vermal lobules VIII–X was 6.97% in
PNC and 6.48% in HCP, and the R2 of SFO MD-derived TWAS
PRS was 3.8% in PING and 2.41% in PNC.
To evaluate the additional prediction power that TWAS PRS
has on the top of traditional GWAS PRS, we next include both
GWAS and TWAS PRS together as predictors in one linear model
to predict the above 28 TWAS-significant ROI volumes
(Method). Compared to the linear model with TWAS or GWAS
PRS only, we found that the prediction accuracy was improved
for most ROIs when using both of the two types of PRS (Fig. 5).
Conditioning on GWAS PRS, TWAS PRS can additionally
explain 0.33–5.22% of phenotypic variance (Supplementary
Data 19, Supplementary Fig. 12). The two PRS together can
have 1.48–9.02% prediction R2 (Supplementary Data 20, Supple-
mentary Fig. 13). For example, the R2 of cerebellar vermal lobules
VIII–X became 7.94% in PNC and 9.02% in HCP, in which
TWAS PRS additionally contributed 5.22% and 3.66% for PNC
and HCP, respectively. On the other hand, conditioning on
TWAS PRS, GWAS PRS increased the R2 by 0.02–4.65%
(Supplementary Data 21, Supplementary Fig. 14). These results
clearly demonstrate the unique value of TWAS PRS for complex
traits prediction and suggest that combining both GWAS and
TWAS PRS can achieve better prediction accuracy.
We also examined the performance of each reference panel on
these significant traits. There was a significant linear relationship
between the panel sample size and average prediction R2 (48
GTEx reference panels, simple correlation= 0.53, p value=
1.21 × 10−4, Supplementary Fig. 15), which means that currently,
the panel sample size may dominate the performance of TWAS
PRS analysis regardless of the tissue specificity59. Among the
brain tissue panels, we found that cerebellum tissue had the
largest sample size and also showed the highest average R2
(Supplementary Data 22), further supporting the importance of
reference panel sample size. Thus, we expect that a reference
panel with a larger sample size will be available and can improve
the prediction power of TWAS PRS.
Discussion
In this study, we applied TWAS methods on 211 neuroimaging
traits to identify genes, whose imputed expression levels were
associated with brain structure variations. Using a cross-tissue
approach, our main discovery analysis identified 138 additional
genes and validated 29 significant genes at stringent Bonferroni
correction p value thresholds. Conditional analysis and compar-
ison with GWAS variant-level results suggested that the identi-
fication and validation of additional genes reflect the ability of
TWAS to reduce the testing burden and to combine the small
genetic variant effects. We also performed brain tissue-specific
TWAS and illustrated the unique strengths of cross-tissue TWAS
in conditional and enrichment analyses. Lots of brain structure-
related genes were known genetic factors for a wide range of
complex traits, ranging from physical traits, cognition, mental
disease/disorders, blood assays, to lifestyle, which extend the
potential applications of neuroimaging traits. Some of these
genetic overlaps were additionally highlighted by a TWAS ana-
lysis of other complex traits.
The present study faces some limitations. First, as these results
are purely based on statistical associations, it is hard to draw
conclusions about the underlying causality and prioritize causal
genes43,107. This is also one of the main challenges for most of the
current TWAS approaches49. Follow-up experimental validation
is a clear need to confirm TWAS results and pinpoint the causal
genes of brain structure changes. In addition, colocalization
analysis (such as fastENLOC) can also help prioritize genes
having more evidence of causal association. Second, the brain
tissue-specific TWAS did not yield much additional results
compared with the previous GWAS, and brain tissue panels did
not show better prediction accuracy than non-brain tissues in
gene-based PRS analysis. Both of the two observations support
the use of multiple tissues in our analysis to increase testing




















































































































































































































































































































































































































































































































































































Fig. 3 Overlapping cross-tissue TWAS-significant genes between neuroimaging traits (n= 19,629 subjects for ROI volumes and 17,706 for DTI
parameters) and other complex traits and clinical outcomes. The gene-level associations were estimated and tested by the cross-tissue UTMOST
approach (https://github.com/Joker-Jerome/UTMOST). We adjusted for testing 211 neuroimaging traits (p value threshold 1.04 × 10−8) and 16 other
traits (p value threshold 1.37 × 10−7) with the Bonferroni correction, respectively. The x axis provides the IDs of the neuroimaging traits. The y axis lists the
16 other traits, and Supplementary Data 15 details the resources of their GWAS summary statistics and the sample sizes of corresponding studies.
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interpretation of TWAS results even more complicated. The
better performance of cross-tissue analysis may be partially
explained by the fact that multi-tissue approaches additionally
evaluate cross-tissue evidence108,109. In addition, though gene-
based PRS had much better power in association tests than SNP-
based polygenic scores, their prediction accuracies were similar.
These limitations may be due to the fact that current brain tissue
reference panels, like many other tissues, do not have large
sample sizes, and/or the associated gene expression imputations
may be of low quality. For example, imputations using genetic
variants with low frequency may not be accurate when the
reference panel sample size is small. Despite these limitations,
TWAS has been holding and delivering to the promise of
becoming a powerful supplement to traditional GWAS in ima-
ging genetics studies. In our study, many additional gene-trait
associations were discovered and the underlying genetic overlaps
among complex traits were substantially expanded. With better
brain tissue gene expression reference panels and more neuroi-
maging GWAS data sets available, future TWAS analyses of
neuroimaging traits are expected to show the value of tissue
specificity and improve our understanding of the genetic basis of
human brain.
Methods
GWAS summary statistics data sets. We made use of GWAS summary statistics
to test for gene-trait associations in our TWAS study. The GWAS summary-level
were from six studies, including the UKB38 (http://www.ukbiobank.ac.uk/resources/)
study, the HCP58 (https://www.humanconnectome.org/) study, the PING57 (http://
www.chd.ucsd.edu/research/ping-study.html) study, the PNC55 (https://www.ncbi.
nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000607.v1.p1) study, the
ADNI56 (http://adni.loni.usc.edu/data-samples/) study, and ENIGMA224 (GWAS of
subcortical volumes) and the ENIGMA-CHARGE34 collaboration (http://enigma.ini.
usc.edu/research/). More information about original GWAS design can be found in
Zhao et al.38 and Zhao et al.39 for UKB, ADNI, HCP, PING, and PNC studies; and
in Hibar et al.24 and Adams et al.33 for ENIGMA studies. Details about GWAS on
validation cohorts (HCP, PING, PNC, ADNI, and ENIGMA) were also provided
in Supplementary Note. For discovery, we used the GWAS summary statistics of the
UKB study. Then the GWAS results of the other studies were used for validation, see
Supplementary Data 23 for a summary of sample size, IDs, names, and modalities of
the analyzed neuroimaging traits of each GWAS. To explore genetic overlaps, we
also performed TWAS analysis for 16 brain-related complex traits, see Supple-
mentary Data 15 for these data resources.
Cross-tissue TWAS analysis by UTMOST. Cross-tissue TWAS analysis was
performed for each trait using the UTMOST software (https://github.com/Joker-
Jerome/UTMOST). We performed UTMOST analysis using GTEx v6 and v8
reference panels separately. Details about UTMOST model training using GTEx v8
data can be found in Supplementary Note. We first run a single-tissue association
test for each GTEx reference panel (44 panels in v6 and 49 panels in v8, respec-
tively) using the above GWAS summary statistics as input. There were 22,694
candidate genes considered in UTMOST. Second, the gene-trait associations in all
panels (tissues) were combined by the GBJ test (https://cran.r-project.org/web/
packages/GBJ/, R version 3.5.0). We used the pre-trained cross-tissue imputation
models and pre-calculated covariance matrices provided by UTMOST. For the 211
neuroimaging traits in the UKB cohort, we also performed a brain tissue-specific
version of UTMOST analysis that only combined the brain tissues in GTEx (10
tissues in v6 and 13 tissues in v8, respectively). We applied the Bonferroni cor-
rection to account for all candidate genes and traits analyzed in each data set.
Specifically, the significance threshold was 5 × 10−2/22,694/211 in UKB, PING,
PNC, and HCP cohorts, 5 × 10−2/22,694/101 in ADNI cohort, and 5 × 10−2/
22,694/16 in the analysis of 16 other complex traits and clinical outcomes. For each
cohort, we obtained a list of significant associations for GTEx v6 and v8 versions,
respectively. We reported genes that were either (1) significant in both versions; or
(2) significant in one version and at least one of its neighboring (within ±1MB
window) gene was significant in the other version.
Comparison with previous GWAS findings. We compared TWAS-significant
genes with those identified in the same UKB cohort by MAGMA gene-based
association analysis and FUMA functional gene mapping analysis, which can be
found in previous GWAS (Supplementary Tables 12 and 15 of Zhao et al.39 for ROI
volumes and Supplementary Tables 14 and 16 of Zhao et al.40 for DTI parameters,
respectively). For each significant gene-trait association, we also explored whether
any genetic variant of this gene region (with 1MB window on both sides) had been
linked to this neuroimaging trait by checking the smallest p value in corresponding
GWAS. For TWAS-significant genes that were not identified in GWAS, we used
NHGRI-EBI GWAS catalog (version 2019-10-14, https://www.ebi.ac.uk/gwas/) to
look for their reported associations with brain structure traits and any other traits.
We summarized the traits that frequently reported for these genes, such as physical
measures (e.g., height, waist-to-hip ratio, heel bone mineral density, body mass
index), cognitive functions (such as general cognitive ability, cognitive perfor-
mance), intelligence, educational attainment, math ability (such as highest math
class taken and self-reported math ability), reaction time, neuroticism, neurode-
generative diseases (such as Alzheimer’s disease and Parkinson’s disease), neu-
ropsychiatric disorders (such as major depressive disorder, schizophrenia, and
bipolar disorder), coronary artery disease, and mean corpuscular hemoglobin.
Cross-tissue analysis conditional on the most significant GWAS signal. The
TWAS gene expression imputation model can be viewed as a weighted sum of
multiple genetic variants. If certain variant has a relatively large weight, the
imputed gene expression could be driven by a single GWAS signal. In order to look
at how many significant TWAS signals could be dominated by a single genetic
variant, we rerun TWAS analysis in UKB cohort conditional on the most sig-
nificant variant used in the UTMOST imputation model (R version 3.5.0). First, for
each reference panel, we considered a simple linear model
Phenotype ~ imputed gene expression+ variant,
where the variant conditioned on was the most significant variant in previous
GWAS of this phenotype in the same UKB cohort. Then, similar to cross-tissue
TWAS analysis, single-tissue conditional p values of the imputed gene expression
were combined by the GBJ test across the GTEx reference panels (44 panels in
GTEx v6 and 49 panels in GTEx v8, respectively).
Chromatin interaction enrichment analysis. The chromatin interaction enrich-
ments between significant and non-significant genes were tested using the Wil-
coxon rank sum test (R version 3.5.0). For the adult neural Promoter Capture Hi-C,
































































































































































Fig. 4 Prediction accuracy (incremental R2) of gene-based polygenic risk
scores constructed by UKB TWAS results (n= 19,629 subjects) on the
four independent data sets. The x axis lists the four independent cohorts
(ADNI, HCP, PING, and PNC) and the y axis lists the ROI volumes. The
displayed numbers are the proportions of phenotypic variation that can be
additionally explained by UKB TWAS-derived gene-based PRS.
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overlapping gene with CHiCAGO Enrichment Score >596. The enrichment was
tested separately in four cell types, including iPSC-induced excitatory neurons,
iPSC-derived hippocampal DG-like neurons, iPSC-induced lower motor neurons,
and primary astrocytes. The Wilcoxon rank sum test was separately performed for
the significant genes obtained from cross-tissue TWAS analysis, FUMA/MAGMA,
and brain tissue-specific TWAS analysis.
Gene-based TWAS polygenic risk prediction. Gene-based polygenic profiles
were created to assess the out-of-sample prediction power of the UKB TWAS
results. In this analysis, we used the individual-level phenotype and genetic data,
whose processing steps were detailed in the previous GWAS39,40. The FUSION
software and database (http://gusevlab.org/projects/fusion/) were used to impute
gene expression levels in UKB, ADNI, HCP, PNC, and PING data sets using
individual-level genetic data. We performed imputation for 52 different reference
panels (Supplementary Data 22). In training data (UKB), we estimated the effect
size of each imputed gene expression in a linear regression model, whereas
adjusting for the age (at imaging), age-squared, sex, age-sex interaction, age-
squared-sex interaction, as well as the top 40 genetic principle components pro-
vided by UKB110 (Data-Field 22009). For ROI volumes, we also included total
brain volume (for ROIs other than total brain volume itself) as a covariate. The
gene-based TWAS PRS were generated in testing data by summarizing across
imputed gene expressions, weighed by their effect sizes estimated from the training
data. We tried a series of p value thresholds for predictor selection: 1, 0.8, 0.5, 0.4,
0.3, 0.2, 0.1, 0.08, 0.05, 0.02, 0.01, 0.001, 1 × 10−4, 1 × 10−5, 1 × 10−6, 1 × 10−7, and
5 × 10−8. Thus, 17 polygenic profiles were generated for each neuroimaging trait
and we reported the best prediction power that can be achieved by a single profile
of them in the single reference panel. The association between polygenic profile and
trait was estimated and tested in linear regression model (R version 3.5.0),
adjusting for the effects of age and sex. The additional phenotypic variation that
can be explained by polygenic profile (i.e., the incremental R2) was used to measure
the prediction power. Next, we additionally considered the best variant-based
GWAS PRS reported in Zhao et al.39 and re-evaluated the incremental R2. Spe-
cifically, we considered the following four simple linear models
Phenotype ~ covariates (m1),
Phenotype ~ TWAS PRS+ covariates (m2),
Phenotype ~ GWAS PRS+ covariates (m3), and
Phenotype ~ TWAS PRS+GWAS PRS+ covariates (m4).
We estimated the incremental R2 of TWAS PRS conditioning on GWAS PRS
using models m4 and m3, the incremental R2 of GWAS PRS conditioning on
TWAS PRS using models m4 and m2, and calculated the additional phenotypic
variation that can be jointly explained by GWAS and TWAS PRS using models m4
and m1. More details about constructing and evaluating gene-based PRS can be
found in Supplementary Note.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data used in this work were obtained from publicly available data sets: the UK Biobank
(UKB) study, the Human Connectome Project (HCP) study, the Pediatric Imaging,
Neurocognition, and Genetics (PING) study, the Philadelphia Neurodevelopmental Cohort
(PNC) study, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study, and
ENIGMA2 & the ENIGMA-CHARGE collaboration. For the first five data sets, the raw
MRI, covariates, and SNP data are available from each data resource: UK Biobank, http://
www.ukbiobank.ac.uk/resources/;PING, http://pingstudy.ucsd.edu/resources/genomics-core.
html/; PNC, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000607.v1.p1/; ADNI, http://adni.loni.usc.edu/data-samples/; and HCP,
https://www.humanconnectome.org/. The GWAS summary statistics can be obtained at
https://github.com/BIG-S2/GWAS and http://enigma.ini.usc.edu/research/. In addition, we
used other 16 sets of publicly available GWAS summary statistics shared by several GWAS
databases. These data resources are summarized in Supplementary Data 15. The FUSION
database used in this study is available at http://gusevlab.org/projects/fusion/.
Fig. 5 Prediction accuracy (incremental R2) of gene-based polygenic risk scores constructed by UKB-derived TWAS summary statistics (TWAS PRS),
variant-based PRS constructed by UKB-derived GWAS summary statistics (GWAS PRS), and both of them (GWAS PRS+ TWAS PRS) on the four
independent data sets (n= 19,629 subjects). The x axis lists 28 ROI volumes whose TWAS PRS are significant in all the four data sets after the Bonferroni
correction and the y axis lists the proportions of phenotypic variation that can be additionally explained by PRS.
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Code availability
We made use of publicly available software and tools, especially the UTMOST (https://
github.com/Joker-Jerome/UTMOST) and the FUSION (http://gusevlab.org/projects/
fusion/). The analysis code is freely available at https://doi.org/10.5281/zenodo.4649360111.
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